MRK has been the topic of several other reports. UBS Group set a €120.00 ($148.15) price objective on Merck KGaA and gave the stock a buy rating in a research note on Monday, January 8th. Nord/LB restated a neutral rating on shares of Merck KGaA in a research note on Wednesday, December 27th. Warburg Research set a €115.00 ($141.98) price objective on Merck KGaA and gave the stock a buy rating in a research note on Wednesday, March 7th. JPMorgan Chase & Co. set a €95.00 ($117.28) price objective on Merck KGaA and gave the stock a neutral rating in a research note on Thursday, January 4th. Finally, Sanford C. Bernstein set a €115.00 ($141.98) price objective on Merck KGaA and gave the stock a buy rating in a research note on Wednesday, November 15th. Twelve analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and an average price target of €101.77 ($125.65).
Merck KGaA (FRA MRK) opened at €77.70 ($95.93) on Monday. Merck KGaA has a one year low of €76.60 ($94.57) and a one year high of €115.00 ($141.98). The stock has a market capitalization of $10,110.00 and a price-to-earnings ratio of 12.99.
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.